Company / Capital Expenditures
Catalyst Pharmaceuticals Partners, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$58.0K
FY2025
5-year range
$29.0K / $1.0M
FY2021-FY2025
Trend
-89.6%
vs FY2024
Sector context
#176 of 195
Health Care
What the data says
Among 195 Health Care companies, Catalyst Pharmaceuticals Partners, Inc. is in the bottom 10% for capital expenditures. Capital Expenditures has fluctuated over the past 10 years, ranging from $11,000 in FY2020 to $1M in FY2021.
Based on SEC 10-K filings.
$58,000 in FY2025 with a 5-year CAGR of +39.4%.
Declined from $231,000 to $58,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +26.0%
- 5-Year CAGR
- +39.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 195This company $58.0K Sector average $116.9M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +39.4%, indicating consistent growth.
- In FY2025, capital expenditures decreased 89.6% year-over-year.
- Ranks #176 out of 195 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 4.78 (safe zone, above 2.9 threshold)
- Strong profit margin: 33.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.0K | -89.6% |
| FY2024 | $556.0K | +140.7% |
| FY2023 | $231.0K | +696.6% |
| FY2022 | $29.0K | -97.2% |
| FY2021 | $1.0M | +9181.8% |
| FY2020 | $11.0K | -42.1% |
| FY2019 | $19.0K | -79.4% |
| FY2018 | $92.0K | +292.2% |
| FY2017 | $23.5K | -75.6% |
| FY2016 | $96.1K | +309.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026